Therefore, it is of great importance to further study the characteristics of the immune microenvironment of EGFR mutation-positive NSCLC and the mechanism of primary ICIs resistance and explore ways to reverse drug resistance and new treatment modes, which will hopefully open up the way for immunotherapy of EGFR mutation-positive NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.